An evaluation of comprehensiveness, feasibility and acceptability of a fertility awareness educational tool

R.R. Bayoumi, S. van der Poel, E.Z. El Samani, J. Boivin

Cardiff Fertility Studies Research Group, School of Psychology, Cardiff University, Cardiff, UK; Population Council, New York, USA; Department of Community Medicine, School of Medicine, Alfad University for Women, Khartoum, Sudan

* Corresponding author. E-mail address: boivin@cardiff.ac.uk (J. Boivin).

Rasha Bayoumi is a Sudanese PhD student at Cardiff University, working on fertility awareness with a focus on low- and middle-income countries (LMIC).

Abstract The World Health Organization (WHO) and World Bank have identified infertility as a global public health issue. Since the 1980s, WHO has advocated for a focus on prevention, especially where the burden of prevalence is highest, specifically in women from low- and middle-income countries (LMIC). The aim of the two studies presented here is to demonstrate a process to enhance implementation efforts in fertility awareness programmes that could assist in preventing some forms of infertility, and increase understanding of factors that could result in fertility problems. The fertility status awareness tool (FertiSTAT) for the Middle East was adapted to provide an illustrative example of requirements for region- or country-specific adaptation. The mixed methods approach used included a survey of international medical experts concerning the comprehensiveness of risks included in the original FertiSTAT (Study I), and stakeholder meetings to assess the feasibility and acceptability of using an adapted FertiSTAT in the Middle East (Study II). The results indicate that the content of the original FertiSTAT was acceptable but not comprehensive in its coverage of potential risk factors; for example, it did not include genital tuberculosis, human immunodeficiency virus, consanguineous relationships and female genital mutilation/cutting. Furthermore, stakeholder meetings revealed that implementation in the Middle East would be enhanced by the use of more culturally sensitive wording. The data highlight the importance of implementation research with participants from LMIC, and the need for standardized protocols for adaptation of any fertility awareness programme or tool before practical application.

© 2018 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

KEYWORDS: infertility, fertility awareness, education, sociocultural, geographic and economic influences, feasibility and acceptability, FertiSTAT, global health, low- and middle-income countries
Introduction

Prevention focus

The World Health Organization (WHO) and World Bank have identified secondary infertility as a global public health issue (WHO/World Bank, 2011). WHO has advocated for a focus on the prevention of secondary infertility, especially in low- and middle-income countries (LMIC) where prevalence is highest (Mascarenhas et al., 2012; Van der Poel and World Health Organization, 2012). The prevention of fertility problems and promotion of ‘fertility care’ (Zegers-Hochschild et al., 2017) is addressed in some higher income countries and settings (National Women’s Health Policy, Australia; Macaluso et al., 2010), but is under-researched and underserved in LMIC and lower-resource settings. The gap in fertility care should be addressed to ensure that policy meets reproductive needs across the lifespan, and to promote equity of access through knowledge about these issues in LMIC (Van der Poel and World Health Organization, 2012). Improvements in fertility care could also have broader health impacts through improvements in prepregnancy health. Addressing an unmet need for family planning and infertility services through the provision of universal access to sexual and reproductive health care are national targets within the sustainable development goals (United Nations General Assembly, 2015), supported through the WHO global reproductive health strategy (WHO, Reproductive Health and Research, 2004). WHO considers its intervention targets in reproductive health, including fertility care, as being ‘of equal weight’ to strengthen the attainment of sexual health as a whole (WHO, 2017). One important aspect of fertility care is improving awareness of the prevention of infertility by highlighting factors that can have a negative impact on fertility or cause fertility problems.

Fertility awareness tools

‘Fertility awareness’ has been proposed to include knowledge of reproduction, fecundity, fecundability, related risk factors and reproductive options (Zegers-Hochschild et al., 2017). Educational and information tools aimed at increasing public and self-awareness about reproductive health and fertility care have been developed recently in high-income countries. These tools use diverse methods to increase awareness including: (i) websites dedicated to fertility that tailor the information which visitors receive according to the risks they present on the site (e.g. ‘yourfertility’ website; Hammarberg et al., 2013); (ii) public health initiatives that use self-assessment tools as a hook to attract people to sites that provide relevant fertility education (e.g. ‘test your fertility’; De Cock, 2011); and, more recently (iii) fertility assessment clinics where people can have their fertility evaluated through history-taking and biomedical tests (Hvidman et al., 2015; Petersen et al., 2015). This article reports two studies describing the process used to examine whether FertiSTAT, a fertility awareness tool developed in the UK, could be acceptable for dissemination and implementation within other sociocultural contexts.

FertiSTAT

FertiSTAT was developed as a self-administered tool for women to increase personal awareness of risk factors that negatively impact ability to achieve a pregnancy [available in printed and online versions; see Bunting and Boivin, 2010 and online supplementary material]. The tool uses 22 lifestyle and reproductive questions (i.e. risk indicators) to generate a risk profile and, based on this, personalized fertility guidance and suggested actions (e.g. to change behaviour, monitor symptoms until ready to attempt pregnancy, or seek medical advice now), weighted for importance via a colour-code system. The tool is appropriate whether women are trying to become pregnant or are using contraception. FertiSTAT was designed to assist women make informed decisions about risks (e.g. lifestyle) and to know when to seek timely medical advice if desired. The risk indicators were identified from empirical research as showing a reliable association with infertility, which has been medically defined as the inability to become pregnant after 12 months of unprotected intercourse or due to other medical or functional diagnoses of a reproductive disorder (Zegers-Hochschild et al., 2009, 2017). The FertiSTAT risk indicators are global and are assumed to operate similarly on fertility wherever people reside (e.g. similar effects of smoking on fertility across countries). Using a multifactorial weighted model, FertiSTAT was shown to discriminate to a high degree (i.e. 85.8%) between fertile women and those who had been medically diagnosed and confirmed infertile (Bunting and Boivin, 2010). FertiSTAT can assist in public health campaigns about fertility problems, and has been used in Belgium (e.g. ‘test your fertility’; De Cock, 2011) and international media (Portugal, Japan, UK), but has not been evaluated or used in the Middle East to date.

FertiSTAT was selected over other available public awareness options based on its strengths, namely more comprehensive risk coverage, use of critical thresholds for each risk (e.g. number of cigarettes smoked, kilograms overweight), weighting of risks (e.g. absence of periods versus irregular periods), consideration of additive relationships between risks (age, years infertile), validation through case–controlled research studies (as described) and low cost (Bunting and Boivin, 2010). FertiSTAT is inexpensive because it comprises one sheet of paper and does not require maintenance compared with other options (e.g. apps and websites). This advantage is critical for successful dissemination in many countries and settings, especially LMIC. Despite all of the advantages listed, it was not known whether FertiSTAT would be appropriate for wider global use.

Geographic variation in risk

It is known that the global distribution of disease and the corresponding patterns of health risks vary according to geography (WHO, 2009). Variations in risks for fertility problems and infertility have been explored in narrative reviews (Bosdou et al., 2016; Ericksen and Brunette, 1996; Leke et al., 1993; Sharma et al., 2009). These reviews suggest that variations in the prevalence of cultural practices (e.g. consanguineous marriages, female genital mutilation/cutting), communicable disease [e.g. human immunodeficiency
Feasibility and cultural appropriateness

The usefulness of evidence-based educational tools is improved if tools are culturally appropriate (Healey et al., 2017). The effectiveness of addressing risk factors through tailored educational health messages has been demonstrated (Noar, 2006), including in reproductive health (Baird, 2009). Adapting evidence-based tools and interventions developed in one country for another raises several issues about feasibility (Bowen et al., 2009) and cultural appropriateness (Kreuter et al., 2003) that could be addressed through stakeholder meetings. Feasibility data help determine whether further evaluation of a health intervention (e.g. service, product) is warranted. Feasibility can cover diverse components: first, acceptability to providers and users (e.g. suitability, attractiveness); second, demand (e.g. individual or organizational intention to use); third, practicality (e.g. resources needed); and fourth, dissemination and implementation issues (e.g. constraints) (Bowen et al., 2009). Consultation with stakeholder groups and users prior to adaptation is useful to elicit relevant, culturally appropriate information (Kreuter et al., 2003). Stakeholders can help adapt tools to the surface characteristics of a target group (e.g. appearance and language) or to deeper sociocultural characteristics (e.g. values, beliefs) that might affect their implementation and effectiveness (Resnicow et al., 1999). The exchange between attendees in a stakeholder meeting could allow more diverse opinions to emerge than with individual surveys. A systematic review of studies comparing health and mental health services with and without culturally adapted interventions showed better outcomes among the latter for a range of services (e.g. improved uptake of HIV tests, decreases in alcohol-induced problem behaviour; Healey et al., 2017). These findings support an examination of the feasibility and sociocultural appropriateness of using awareness tools such as FertiSTAT outside of the setting of their initial development.

Aim

The aim of this work was to determine the perceived comprehensiveness, feasibility of use and acceptability of FertiSTAT among multiple stakeholders (providers and users) in settings outside of the development context (UK). A mixed method process of adaption was undertaken. In Study I, the aim was to ascertain the comprehensiveness of the risk factors included in the original FertiSTAT. A survey of doctors practising in diverse LMIC worldwide was used to identify additional risk factors for inclusion when adapting FertiSTAT for wider use. In Study II, stakeholder meetings were used to collect qualitative data about the feasibility and acceptability of using an adapted FertiSTAT that included the additional risk factors identified in Study I in the Middle Eastern region.

Study I. Survey of medical experts to assess the comprehensiveness of the FertiSTAT risk factors and to identify potentially relevant additional risk factors

Materials and methods

Participants and recruitment

A list of experts active in education and training in LMIC (n = 106) was generated with input from a former Director of Medical Education and the International Federation for Fertility Societies, and by searching contact information for fertility clinic websites in Africa and the Middle East (n = 44). These medical experts were invited to participate in the survey. Eligibility criteria included being a medical doctor, and actively assessing and treating individuals with potential fertility problems. Participants were not provided any financial incentive for involvement. The School of Psychology (Cardiff University) Ethics Committee provided review and approval for the project.

Materials

Study questions were embedded in an online survey generated with Qualtrics (Qualtrics, Provo, UT, USA). All survey questions were indicated optional. The questionnaire was developed specifically for the study and comprised three sections. First, the 22 lifestyle and reproductive risk factors in the original FertiSTAT were presented for information to make respondents aware of the risks already included. Second, a ‘structured list’ of additional risks not included in the original FertiSTAT was presented, which included medical conditions associated with fertility problems and additional risk factors identified from narrative literature reviews of risk factors in diverse regions that include LMIC and other lower-resource settings. For each item on the ‘structured list’, participants were asked to indicate whether the item should be considered for inclusion as a risk factor for female infertility in an adapted FertiSTAT (yes/no). An open text box provided space to provide reason(s) or justification(s) for inclusion of the particular risk factor. The third and final section was a second open text box that asked participants to specify any other risk factor that they felt was relevant to their country of practice (hereafter ‘participant-generated list’). Again, participants were asked to indicate a reason(s) or justification(s) for inclusion of their proposed risk factor in an adapted FertiSTAT tool.

Background sociodemographic and medical practice questions were asked (e.g. country of practice, type of specialization, number of years practising, healthcare sector). Country of practice was classified into income countries (low, lower-middle and upper-middle income) according to the Development Assistance Committee (DAC) list of overseas development aid (ODA) recipients (Organisation for Economic Co-operation and Development, 2017).
Procedure

Participants were invited to the study via e-mail and instructed to click on a hyperlink that led them to information about the study, the consent form and the survey. At the end of the survey was a ‘submit’ button that participants clicked to submit their data.

Data analysis

Reasons given for inclusion of new risks were grouped according to type (medical, reproductive or lifestyle). When participants gave multiple reasons, descriptive statistics were used to report frequency data.

Results

In total, 41 of 150 (27.3%) medical experts participated in the survey. The majority of participants were from Africa and the Middle East (63.4%, n = 26), and most participants (75.6%, n = 31) were from low, lower-middle and upper-middle income countries of ODA recipients. Of these, 51.6% (n = 16) practised in least-developed or low-income countries (Sudan, n = 6; Uganda, Nepal, Kenya, Nigeria, n = 2 each; Egypt, Paraguay, n = 1 each) and 48.4% (n = 15) practised in ODA upper-middle-income countries (South Africa, n = 10; Libya, Tunisia, Turkey, Uruguay, Panama, n = 1 each). Remaining participants (22% of all participants) practised in higher income countries not on the DAC list (Russia, Spain, n = 2 each; Belgium, UK, USA, Kazakhstan, Taiwan, n = 1 each). Of the 33 participants who responded to the training question, almost all (32/33) had specialist training in addition to training in obstetrics and gynaecology (e.g., reproductive medicine or reproductive endocrinology and infertility). On average, years of medical practice was 28.7 [standard deviation (SD) 9.4] and years of fertility practice was 19.3 (SD 10.75). Of the 34 participants who answered the question concerning their setting, 50% (n = 17) were in the private sector alone, five were in the public sector alone, nine were in both sectors, and three were in other settings (e.g., academic institutions). The average number of fertility patients (or couples) with fertility problems managed per week was 31.58 (SD 18.4, median = 30).

Table 1 shows the percentage agreement that risk factors and medical conditions on the ‘structured list’ should be included in an adapted FertiSTAT. The percentage agreement varied, with medical and reproductive conditions (e.g., cancer, HIV) generating higher endorsement for risks than ‘practices’ (e.g., consanguinity). Specifically, 75.9–97.0% of the total sample endorsed additional risk factors arising from infection or communicable diseases (e.g., HIV, genital tuberculosis or postpartum infection), 50.0–86.5% endorsed non-communicable diseases (e.g., diabetes, lupus), and 37.5–54.2% endorsed cultural practices (e.g., female genital mutilation/cutting). Overall, 25 participants suggested other risk factors relevant to their country of practice. Factors included: medical (e.g., medications, thyroid disease), reproductive (e.g., adhesions/fibroids), or lifestyle and environment (e.g., vitamin D deficiency, occupation/exposure). Lifestyle and environment were suggested less commonly.

Table 1 also includes frequency of justifications reported for inclusion of the risk factors. Few participants provided a specific reason, but this depended on the type of risk. For example, more people endorsing a reproductive condition provided a justification than those endorsing a practice. A reason was reported for approximately half of the participant-generated risk factors, mainly for proposed lifestyle risks.

Study II. Assessing the feasibility and acceptability of implementing an adapted FertiSTAT in the Middle East among multiple stakeholders

Methods

Participants and recruitment

Two meetings were held in the Middle East. The first was held in Egypt in November 2016 at the 2016 annual conference of the Middle East Fertility Society (MEFS). The mission of MEFS is to improve fertility care for couples in the Arab world and Middle East through the transfer of medical knowledge and the promotion of scientific research. The MEFS Administration identified 30 medical experts practising in the Middle East and planning to attend the MEFS conference, and sent them an e-mail inviting them to participate in the study. Of the 30 invited, 28 (93.3%) agreed to participate and 21 were able to attend the stakeholder meeting (4 November 2016) facilitated by RRB and SvdP. Seven experts were unable to attend group meetings due to scheduling conflicts, and participated in individual interviews with the facilitators at a later time on the same day as the group session. The second stakeholder meeting was held in Sudan in December 2016 under the guidance and leadership of the National Reproductive Health Programme (NRHP) of the Sudanese Federal Ministry of Health. NRHP sent invitations to policy makers, representatives from women’s and youth groups, and local experts in individual and group qualitative research methodologies in Sudan. Of the 15 individuals invited, 11 were able to attend the meeting facilitated by RRB and JB. The invitations for all meetings included an agenda which stated that the comprehensiveness of an adapted FertiSTAT and the feasibility and acceptability of its use in the Middle East would be discussed. No incentives were offered to attendees, but lunch was provided at both meetings.

Materials and procedure

The FertiSTAT discussed during stakeholder meetings (adapted FertiSTAT) comprised the original 22 risk factors plus an additional five factors endorsed as relevant to LMIC from Study I. Of the 36 risk factors investigated in the survey (15 structured list, 21 patient-generated), five warranted further consideration for inclusion in FertiSTAT due to consensus among survey participants and consistency with extant empirical literature on their importance, exclusion from the originalFertiSTAT, and evidence garnered from ongoing systematic reviews and meta-analysis showing association with fertility (ongoing research). These were: consanguinity, female genital mutilation/cutting, HIV, genital tuberculosis and bacterial vaginosis, and water-pipe smoking as an additional method of using tobacco. A section on non-communicable diseases (e.g., diabetes) was also included. Prior to the meetings, collaborators (EFS, former Director of MEFS) advised the meeting facilitators that the use of a self-administered tool in the Middle East might
| Risk factors Endorsed n/N (%) | Principal reasons given to justify endorsement (n/N of responses) | 1a. Structured list | 1b. Participant-generated list |
|--------------------------------|------------------------------------------------------------------|-------------------|-----------------------------|
| **Practices**                  |                                                                  |                   |                             |
| FGM/C                          | 13/24 (54.2)                                                     | 2/13 (15.4)       | 3/25 (12.0)                 |
| Consanguinity                  | 13/26 (50.0)                                                     | 1/13 (7.7)        | 0/1 (0)                     |
| Water-pipe smoking             | 9/24 (37.5)                                                      | 3/9 (33.3)        | 0/1 (0)                     |
| Bacterial vaginosis            | 12/27 (44.4)                                                     | 0/12 (0)          |                            |
| HIV                            | 22/29 (75.9)                                                     | 4/22 (18.2)       | 0/1 (0)                     |
| GTB                            | 32/33 (97.0)                                                     | 2/32 (6.3)        | 0/1 (0)                     |
| Postabortion infection         | 34/36 (94.4)                                                     | 2/34 (5.9)        | 0/1 (0)                     |
| Postpartum infection           | 28/30 (93.3)                                                     | 2/28 (7.1)        | 0/1 (0)                     |
| Repeated D&C                   | 26/30 (86.7)                                                     | 1/26 (3.8)        | 0/1 (0)                     |
| Cervical electrocautery        | 14/25 (56.0)                                                     | 0/14 (0)          | 0/1 (0)                     |
| Diabetes                       | 26/35 (74.3)                                                     |                   |                             |
| **Reproductive factors**       |                                                                  |                   |                             |
| HIV                            | 22/29 (75.9)                                                     | 4/22 (18.2)       | 0/1 (0)                     |
| GTB                            | 32/33 (97.0)                                                     | 2/32 (6.3)        | 0/1 (0)                     |
| Postabortion infection         | 34/36 (94.4)                                                     | 2/34 (5.9)        | 0/1 (0)                     |
| Postpartum infection           | 28/30 (93.3)                                                     | 2/28 (7.1)        | 0/1 (0)                     |
| Repeated D&C                   | 26/30 (86.7)                                                     | 1/26 (3.8)        | 0/1 (0)                     |
| Cervical electrocautery        | 14/25 (56.0)                                                     | 0/14 (0)          | 0/1 (0)                     |
| Diabetes                       | 26/35 (74.3)                                                     |                   |                             |
| **Medical conditions**         |                                                                  |                   |                             |
| Kidney disease                 | 22/29 (75.9)                                                     | 4/22 (18.2)       | 0/1 (0)                     |
| SLE (lupus)                    | 25/34 (73.5)                                                     | 7/25 (28.0)       | 0/1 (0)                     |
| Sickle cell anaemia            | 16/32 (50.0)                                                     | 0/1 (0)           | 0/1 (0)                     |
| Cancer                         | 32/37 (86.5)                                                     |                   |                             |
| **Medical**                    |                                                                  |                   |                             |
| Medications (pharmaceutical,   | 3/25 (12.0)                                                     | 0/3 (0)           | 0/3 (0)                     |
| psychotropic or traditional)   |                                                                  |                   |                             |
| Male factor (e.g. cancer       | 6/25 (24.0)                                                     | 0/6 (0)           | 0/6 (0)                     |
| treatment)                     |                                                                  |                   |                             |
| Thyroid disease/treatment      | 7/25 (28.0)                                                     | 0/7 (0)           | 0/1 (0)                     |
| Anaemia                        | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Autoimmune diseases            | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Cushing syndrome               | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Chronic liver disease          | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Inflammatory bowel disease     | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Adhesions/fibroids             | 2/25 (8.0)                                                      | 0/2 (0)           | 0/1 (0)                     |
| Vaginitis                      | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Dyspareunia                    | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Pelvic tuberculosis            | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Pregnancy-related infection    | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Hyperprolactinaemia            | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Low vitamin D                  | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Occupation/exposure            | 3/25 (12.0)                                                     | 0/3 (0)           | 0/3 (0)                     |
| IUD                            | 2/25 (4.0)                                                      | 0/2 (0)           | 0/2 (0)                     |
| Extreme exercise               | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
| Undernutrition/anorexia        | 1/25 (4.0)                                                      | 0/1 (0)           | 0/1 (0)                     |
not be feasible given education and literacy levels among typical clients and patients. Therefore, the authors developed two versions of the adapted FertiSTAT for discussion with stakeholders: a flipchart version appropriate for community health workers (trained individuals from the community who are not necessarily medically trained) to use with clients; and a checklist version appropriate for healthcare providers (physicians and nurses) to use with their patients. The flipchart is one of the methods used by WHO and other non-government organizations (NGOs), such as the Population Council, at the level of primary care in regions of lower literacy when communicating reproductive health issues (e.g., contraception) (WHO, 2005). The flipchart version was two-sided with one page facing the client and the other facing the provider. The page facing the client depicts information using pictures and simple graphics; the other page faces the service provider and displays corresponding key questions, detailed information and discussion points for the provider to educate the client on the FertiSTAT item. The checklist version showed, on a single page, the list of FertiSTAT risk indicators that providers could check off as affecting the consulting patient. Checklists are used increasingly to efficiently condense a large quantity of information, describe essential evidence-based criteria, and enhance the objectivity and reproducibility of communications between practitioners and patients, including settings where there is low literacy (Hales et al., 2008). As noted, the adapted versions (flipchart, checklist) included 28 items: the 22 original FertiSTAT risk indicators, five additional risk factors identified in Study I, and an item including all the medical conditions. It should be noted that two of the 22 items concerned risk factors for men (mumps during puberty, undescended testicle).

At both meetings, participants were given a presentation regarding the development and use of the original FertiSTAT. The adapted version (flipchart, checklist) was then presented and discussed in relation to comprehensiveness of risk indicators, applicability, feasibility and cultural/regional acceptability. Discussion included specifics of implementation, such as target audience, setting and practicality of use (e.g., format). Due to the sensitivity of the topics, recording devices were not utilized; however, detailed notes (including direct quotes) were taken by SvDP and RRB for the first set of meetings, and by a Sudanese research assistant for the meeting in the Sudan.

Data analysis
RRB and SvDP conducted thematic analysis (Braun and Clarke, 2006) and derived codes from all meeting notes (inductive coding) about perceived feasibility and acceptability of the adapted FertiSTAT. Codes with the same meaning (e.g., ‘population of interest’ and ‘target population’) were combined. Coders discussed and reached agreement on whether each code communicated a unique meaning or fit with other existing codes. Each coder organized codes into main themes, and these were discussed between coders to ensure the cohesiveness of each theme and consistency with the overall meanings in the dataset. Subthemes within the main themes were also identified to facilitate understanding and presentation of the results. Participant quotes were used to illustrate meanings. The use of parentheses within quotations in the results section below indicates text added for clarity, while omitted text is represented using ‘(…’) All illustrative quotations are from medical experts, unless profession is specified. The meeting in which the quote originated has been indicated using M1 (Meeting 1) and M2 (Meeting 2).

Results
The attendees of the first meeting at the MEFS conference were 28 medical experts practising in 10 countries in the Middle East. All were ODA recipients except Saudi Arabia. Countries were low or lower-middle income (Sudan, Egypt, Syria) or upper-middle income (Algeria, Iraq, Jordan, Lebanon, Libya, Turkey). The attendees of the second meeting were 11 stakeholders from Sudan, comprising representatives from: the Ministry of Health (NRHP), medical societies (Sudanese Society of OB/GYN and Sudanese Reproductive Health and Embryology Society), reproductive health expert from the United Nations Population Fund (UNFPA), national NGOs [e.g. Regional Institute of Gender, Diversity, Peace and Rights, Sudan (RIGDPR), HIV Unit of JASMAR Human Security Organization], a previous patient, epidemiologists, medical doctors from local universities (University of Khartoum, Ahfad University, National Ribat University), and medical experts practising in the public and private sectors. As shown in Table 2, thematic analysis resulted in five main themes, described below.

Need for fertility awareness in the Middle East
Fertility awareness was considered to be necessary and timely: “there is a niche for such tools especially because our societies are geared towards childbearing” (M1) due to perceived lack of “information about risk factors”, “misconception about what is a risk” (M1) and lack of knowledge about when to seek medical advice causing people to seek
treatment "too early or too late" (M1). Greater knowledge on these topics would help "reduce the burden" (M1) on healthcare systems and individuals, and potentially reduce the prevalence of known preventable causes of infertility "if they know when to get help" (M1). Participants also spoke more generally about the topic. The social stigma of infertility was highlighted for men: "(...) they (men) deny having the problem because it is shameful, makes him less of a man" (M2); "male infertility is a stigma" (patient, M2). Another issue supporting increasing fertility awareness was misunderstanding of information that people obtained from the internet: "the main problem is the internet, where individuals look up on say PCOS (polycystic ovary syndrome) and immediately find infertility as the end" (M2).

Content acceptability and specific tool changes
There was consensus that, "with some adjustment to the language" (M1), an adapted FertiSTAT could potentially be culturally acceptable and used in the Middle East. The absence of PCOS from the adapted FertiSTAT was noted because it was common in the practice of some doctors: "(...) 30% of my patients have PCOS" (M2).

However, there was conflicting opinion about wording. Some suggested that certain risk factors should be removed, altered or only communicated to specific audiences due to their sensitive nature:

"Sex with multiple partners is unacceptable in a community of husbands and wives (…) the word ‘partner’ particularly should not be used" (M2).

"Items regarding things like multiple partners need to be delivered in a sensitive manner (…) use ‘extramarital affairs’ or ‘previous relationships’ (…) but you have to ask" (M2).

However, others felt that the adapted FertiSTAT tool could be used as designed in their country or clinic setting. The terminology was "comprehensible" with some modification of "medical terminology like endometriosis and PID (pelvic inflammatory disease) (that) should be replaced with more understandable terminology, which would require deliberation at length and with several experts" (M1). Some also felt that wording/phrasing might need to be "country specific (…) or specific to particular community settings (within countries)" (M1).

A reproductive health expert from a Sudanese NGO (RIGDPR, M2) mentioned the importance of the provider in asking about risk factors: "you have to be careful when asking these women (…) your body language, choice of words" (M2).

Target audience
Diverse target audiences were suggested for the adapted FertiSTAT tool. A reproductive health expert from a Sudanese NGO (RIGDPR, M2) suggested that the materials should "target couples who are about to get married" (M2), and a representative from UNFPA in Sudan noted that "school children (and) university students are the main targets" (M2). Recommendations appeared to depend on views of current social norms: "You can’t talk about these things (sex) with people who are not married yet (M1); "Times are changing (…) in some places" (M1). However, in both meetings, integration into existing programmes for young people was recommended. For example, premarital counselling which is "mandatory about certain medical disorders such as HIV and hepatitis B and C to receive a marriage certificate in Egypt" (M2), and "free youth workshops held by the Ministry of Youth, targeting couples who are about to get married and educating them about things like family planning, HIV testing" (RIGDPR, NGO, M2).

| Theme | Summary of theme |
|-------|-----------------|
| Need for fertility awareness in the Middle East | Fertility awareness was endorsed based on societal emphasis on childbearing and perceived widespread misconceptions about fertility and lack of fertility knowledge |
| Content acceptability and suggested tool changes | The content of the adapted FertiSTAT that was acceptable The wording of certain items found to be unacceptable or only acceptable if modified to be better understood and more culturally sensitive |
| Target audience for adapted FertiSTAT | Suggestions for the appropriate age and marital status of the target audience on which to use the adapted FertiSTAT included: couples preparing for marriage, newlyweds and young unmarried individuals (men and women) Suggestions about subgroups (e.g. refugees) as separate target audiences were made |
| Setting for implementation | Regional level settings: disagreement about the possibility of a regional tool Country/community level settings: urban and rural settings may have different needs Possible settings for dissemination and implementation include: schools, primary healthcare facilities, infertility clinics (tertiary level), community and media |
| Need for further research (setting specific) and a working group | Next steps require setting up a working group to finalize the content of the material and oversee necessary regional research Areas for future research: assess implementation in proposed settings and target populations; identify which format would be suitable for which setting; field testing the wording used to appropriately communicate complex, sensitive or stigmatizing topics to determine acceptability and alternatives; evaluate research to ensure highest possible quality of research (empirically sound); ethical problems (e.g. screening) will lead to huge demand and services need to be available |
Other specific targets were “unique subcultures within each country that may have different needs and level of understanding (...) (or) acceptability” (M1). One example was the refugee population “who despite their circumstances are very keen on having children and the need for fertility awareness is acute” (M1). Broader dissemination was also suggested: “these tools should be tested at community level targeting the general population” (M1).

Setting for implementation

The fourth main theme concerned the macro/micro level setting for implementation of fertility awareness tools. There were suggestions that there should be “a Middle East version” (M1) that was tailored to the needs of that specific region. However, others disagreed: there “cannot be a regional tool” and we “cannot (even) have a country tool” and “a regional tool may not be possible but a national tool would be beneficial” (M1). This view was based on the diversity of people within the region or a country, and the exposure to different risks; for example, female genital mutilation/cutting is highly prevalent in Sudan and Egypt, but is almost non-existent in Lebanon and Oman. Further, different settings could have different needs; for example, there may be a “need to develop a rural and an urban version (format) for each country” (M1). A reproductive health expert from a Sudanese NGO (RIGDPR) made a similar suggestion, emphasizing the difference in literacy levels across the country (M2).

At the country/community level, several suggestions for use and dissemination were made, including schools, primary healthcare facilities, infertility clinics (tertiary level), media and community (as described above). There was agreement that the primary healthcare level setting would help reach the widest audience. Several medical experts (M1 and M2) expressed an opinion that the school setting (regardless of age of pupils) would not be appropriate due to the sensitive issues raised (e.g. sexual activity and illegal drug use), but not all agreed. Some felt that adolescents were already exposed to these issues (M1 and M2). Others, including an epidemiologist (M2) and representatives from Sudanese NGOs (M2), expressed the view that “integrating the material in the curriculum of schools and universities would be best” (M2). This was further reinforced by ongoing activities; for example, in Sudan, the “Ministry of Health and Ministry of Education with the support of UNICEF are in the process of rolling out (in schools) an adolescent health module on fertility, targeting ages 10–19 years” (NRHP representative, M2). It was stated that “interventions have to start early (...) first place should be at the school, train the teachers, give the information to the educators” (M2). There was consensus that further research was necessary to ascertain acceptability and utility in schools, and if and how to target different adolescent and young adult age groups (M1 and M2).

In addition, a checklist was suggested for use by nurses or the patients themselves in fertility clinics (tertiary care) prior to the consultation with the fertility specialist (M1 and M2). Although the fertility clinic may seem late for prevention, often couples who attend these clinics are not infertile and do not require fertility interventions, but do require reproductive health education including fertility awareness knowledge. Participants expressed the view that “all my clients are infertile and this (adapted FertiSTAT) would be useless (at this stage)” (M1), while others reinforced the well-known statistic that “we get many (patients) who are NOT infertile, but they think they are, so it (adapted FertiSTAT) would be very helpful” (M1) in making patients aware of risks identifying those who might require medical attention.

The use of media such as television, radio, internet and social media (e.g. Facebook, WhatsApp) was discussed as potential viable dissemination platforms in both meetings. In Sudan, the material could be disseminated in group format rather than one-on-one: “village meetings, community gatherings, rather than individual(ly)” or via print media “in clinics, outpatient departments, magazines” (M2). A representative from a local university (M2) suggested using the flipchart version and taking advantage of existing health promotion programmes like the “rural extension program at Ahfad University” to improve fertility awareness. Every year, Ahfad University sends students to rural villages to deliver health education messages; fertility could be one of these topics. Midwives and healthcare visitors were also suggested as potential local healthcare providers who could be trained to disseminate this information, as they are the “main care providers in rural areas where 80% of deliveries are at home” (M2). Finally, the demographic characteristics of participants (e.g. education, socio-economic status) were perceived to possibly necessitate the use of “different tools/formats for different settings” (M1). For example, the provider flipchart would be useful for settings where individuals have lower education levels, the checklist would be helpful within a fertility care clinic or health centre, and a self-administered questionnaire would be suitable only for settings where potential users are “well educated” (M1).

Need for further research (setting specific) and a working group

More research was thought to be necessary for adapting the original FertiSTAT prior to implementation within the Middle East. The MEFS experts thought that the creation of a working group that could “finalize the content of the material” (M1) and oversee necessary regional research was the logical next step for implementation. In addition, research was needed for wording of guidance to ensure the appropriate assignment of blue, yellow, orange or red flags (M1 and M2). Prospective testing in multifactorial models would be required to detect how these additional risk indicators would alter prediction values compared with the original FertiSTAT prediction capacity (Bunting and Boivin, 2010). These research gaps were perceived to be essential to ensure appropriate guidance or referral (i.e. audience, format, wording) and to maintain the integrity of FertiSTAT as a validated tool. It was noted that the “integration of fertility awareness tools and research regarding testing different formats” would require the involvement of “professional societies” and “public health experts who would be more able to advise on where within existing healthcare services the tools can be integrated and what level of content (difficulty)” (M1). There was concern over research quality, and one participant stated that “the research (would) need to be well-coordinated and implemented (...) one bad application or extreme negative outcome could potentially destroy the whole project (and
working knowledge about poorly known or understood risks, accepted by medical experts. Future research needs to adequately assess or not yet communicated to or practices and their impact on fertility is not robust, not be that evidence about less endorsed risks such as cultural risks that are more highly endorsed. Alternatively, it could tuberculosis) or non-communicable (e.g. diabetes, lupus) risky for fertility than the communicable (e.g. HIV, genital mutilation/cutting, water-pipe smoking) were actually less risks associated with cultural practices (e.g. female genital and literacy. Content and wording were challenged, and flipcharts or checklists were preferred due to lower education client or user in the Middle East, and provider-administered FertiSTAT was not considered to be appropriate for the typical in endorsement because the majority of participants did not provide a reason/justification for endorsing a risk. As FertiSTAT has been empirically validated, any newly endorsed and proposed risk factor needs to be subjected to systematic review and meta-analysis (when feasible) before inclusion in an adapted FertiSTAT is empirically warranted.

Some assumptions made in developing the original FertiSTAT were questioned in the present studies. In the original FertiSTAT, medical conditions (e.g. diabetes) were excluded on the grounds that the general practitioner or disease specialist would have informed affected patients about potential risks to their fertility, making the need to raise awareness of such risks unnecessary in a fertility awareness tool (Bunting and Boivin, 2010). However, the results of Study I suggest that this assumption may not apply widely. Not all participating medical experts knew the fertility effects of the medical conditions examined; for example, 14% did not agree that cancer could be a risk for reduced fertility. This finding is consistent with an international systematic review that postdates the original FertiSTAT, showing that approximately one-third of cancer survivors surveyed did not recall being told about the effects of cancer or its treatment on their fertility or reproductive potential (Tschudin et al., 2010). Of course, it could be that doctors and oncologists know about risks but do not provide information due to low accessibility of treatment or options to resolve infertility. This possibility also needs to be considered. However, providing evidence-based education and information that enables patients to make informed choices, even when these are few, is consistent with ethical medical practice. In turn, evidence gathered from patients who benefit from this knowledge will help to impact national policies that ensure greater access to health prevention and care, which are critical components for all health problems. Together these findings suggest that assumptions underlying inclusion or exclusion of risk factors in fertility awareness tools should be examined, especially when introducing a tool in a new country within settings where there is limited access to universal health care, or where there is inadequate adherence to, or lack of, best practice guidelines in reproductive care or other health areas impacting fertility.

Feasibility and acceptability

The concept of using a tool to increase fertility awareness was accepted and perceived to be feasible. However, some challenges exist. The use of a self-administered version of FertiSTAT was not considered to be appropriate for the typical client or user in the Middle East, and provider-administered flipcharts or checklists were preferred due to lower education and literacy. Content and wording were challenged, and perceived to require being made appropriate for the country
and specific population (married, unmarried). In this case, “appropriate” is in reference to social conventions about permissibility of discussing taboo topics with different members of a community, reinforcing social norms as powerful drivers of medical healthcare-seeking, especially in LMIC (Finlayson and Downe, 2013; Thaddeus and Maine, 1994). It should be noted that hesitation about taboo topics could also be due to the significant penalties or shame of engaging in illegal activities in Muslim countries (e.g. alcohol use; Islam and alcohol, 2012). Together, violation of social or legal norms could be very problematic for individuals and also for medical doctors who learn about them. These issues identified for the Middle East could also be relevant for other countries wanting to adapt FertiSTAT or other fertility awareness tools.

Future research

As noted, research is required to review and synthesize the data available on the risk factors that were not included in the original FertiSTAT and to develop appropriate guidance. Future research should aim to develop a fertility awareness tool for men, as the issue of male fertility was raised in both stakeholder meetings. The original FertiSTAT was developed and validated in women. It includes only two reliable predictors of reduced male fertility (i.e. mumps during puberty, undescended testicle). Since FertiSTAT was published, more rigorous studies of risks and fertilization in men have been performed (e.g. male obesity; Campbell et al., 2015) and it may be possible to generate a valid male FertiSTAT. Testing feasibility and acceptability would also be necessary because perceptions of male fertility and men’s quality of life differ across countries (Sexty et al., 2016), including in the Middle East (Inhorn, 2012). After such steps have been taken, the process of globalizing FertiSTAT and similar tools requires more implementation research to validate their predictive value across countries, and to demonstrate their value in such settings.

Conclusion

The processes used in the present studies concur with cross-cultural adaptation guidelines that recommend consultations with health experts from the target population before implementation (Beaton et al., 2000; Guillemin et al., 1993). Globalizing health awareness should aim to ensure recognition of diversity in the opinions of experts and advisors, with the aim of accommodating the needs of the end-user. The principal lesson learnt through these studies was that fertility awareness tools such as FertiSTAT cannot be superimposed on target populations that might differ from the populations where such tools were originally developed. Although risk factors could have a common underlying mechanism globally, it would be a mistake to assume that this universality necessarily implies similarity in the fertility
risk factor profile to which people are individually exposed globally, or the method by which awareness of risk could be enhanced. FertiSTAT would benefit from inclusion of additional risk indicators in line with its introduction in new countries. This paper has presented a process of adaptation that could be used as other countries and regions become interested in FertiSTAT and other fertility awareness tools. It is critical to address these risk factors in order to sustain healthy fertile lives.

Acknowledgements

The authors wish to thank Professor Ian Cooke who helped generate the list of participants for the survey; the MEFS organizing committee and Prof Johnny Awwad who assisted in the identification of key participants and the organization of the expert meeting during the 2016 Middle East Fertility Society Conference in Egypt; Dr. Dalya El Tayeb, representative of the National Reproductive Health Programme of the Sudanese Federal Ministry of Health, who helped organize the Sudan stakeholder meeting; and Dr. Kawther Mohamed, research assistant, who helped with the Sudan stakeholder meeting. This research was supported by the Economic and Social Research Council, Global Challenges Research Fund (Impact Acceleration Grant No. ES/M500422/1) and the World Health Organization/Human Reproduction Research Programme (WHO/HRP; UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.rbms.2018.06.003.

References

Beaton, D.E., Bombardier, C., Guillemin, F., Ferraz, M.B., 2000. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 25 (24), 3186–3191.

Bosdou, J.K., Kolbianakis, E.M., Tarlatzis, B.C., Fatemi, H.M., 2016. Sociocultural influences on fertility in the Middle East: the role of parental consanguinity, obesity and vitamin D deficiency. Fertil. Steril. 106 (2), 259–260.

Braun, V., Clarke, V., 2006. Using thematic analysis in psychology. Qual. Res. Psychol. 3 (2), 77–101.

Bunting, L., Boivin, J., 2010. Development and preliminary validation of the fertility status awareness tool: FertiSTAT. Hum. Reprod. 25 (7), 1722–1733.

Campbell, J.M., Lane, M., Owens, J.A., Bakos, H.W., 2015. Paternal obesity negatively affects male fertility and assisted reproduction outcomes: a systematic review and meta-analysis. Reprod. BioMed. Online 31 (5), 593–604.

De Cock, G., 2011. Infertility prevention campaign: a multi-stakeholder example from Flanders, Belgium. Hum. Reprod. 26 (Suppl. 1), i58–160.

Eriksen, K., Brunette, T., 1996. Patterns and predictors of infertility among African women: a cross-national survey of twenty-seven nations. Soc. Sci. Med. 42 (2), 209–220.

Finlayson, K., Downe, S., 2013. Why Do Women Not Use Antenatal Services in Low- and Middle-Income Countries? A Meta-Synthesis of Qualitative Studies. PLoS Med. (Retrieved from http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001373).

Frayne, D.J., Verbiest, S., Chelmow, D., Clarke, H., Dunlop, A., Hosmer, J., Menard, M.K., Moos, M.K., Ramos, D., Stuebe, A., Zephyrin, L., 2016. Health care system measures to advance preconception wellness: consensus recommendations of the clinical workgroup of the National Preconception Health and Health Care Initiative. Obstet. Gynecol. 127 (5), 863–872.

Guillemin, F., Bombardier, C., Beaton, D., 1993. Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines. J. Clin. Epidemiol. 46 (12), 1417–1432.

Hales, B., Terblanche, M., Fowler, R., Sibbald, W., 2008. Development of medical checklists for improved quality of patient care. Int. J. Qual. Health Care 20 (1), 22–30.

Hammarberg, K., Setter, T., Norman, R.J., Holden, C.A., Michelmore, J., Johnson, L., 2013. Knowledge about factors that influence fertility among Australians of reproductive age: a population-based survey. Fertil. Steril. 99 (2), 502–507.

Hvidman, H.W., Petersen, K.B., Larsen, E.C., Macklon, K.T., Pinborg, A., Andersen, A.N., 2015. Individual fertility assessment and pro-fertility counselling: should this be offered to women and men of reproductive age? Hum. Reprod. 30 (1), 9–15.

Inhorn, M.C., 2012. The new Arab man: Emergent masculinities, technologies, and Islam in the Middle East. Princeton University Press.

International Federation of Fertility Societies, 2016. IFFS Surveillance 2016. 7th ed. Global Reproductive Health 1(1) pp. 1–143.

Islam and alcohol: Tipsy taboo. 2012. The Economist. August. Retrieved from http://www.economist.com/node/21560543.

Leke, R.J., Oduma, J.A., Bassol-Mayagoitia, S., Bacha, A.M., Grigor, K.M., 1993. Regional and geographical variations in infertility: effects of environmental, cultural, and socioeconomic factors. Environ. Health Perpsect. 101 (Suppl. 2), 73–80.

Macaluso, M., Wright-Schnapp, T.J., Chandra, A., Johnson, R., Satterwhite, C.L., Pulver, A., Berman, S.M., Wang, R.Y., Farr, S.L., Pollack, L.A., 2010. A public health focus on fertility prevention, detection, and management. Fertil. Steril. 93 (1), 16-e1.

Mascarenhas, M.N., Flaxman, S.R., Boerma, T., Vanderpoel, S., Stevens, G.A., 2012. National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys. PLoS Med. 9 (12)e1001356.

National Women’s Health Policy, Australia, d. Retrieved from: http://www.health.gov.au/internet/publications/publishing.nsf/Content/womens-healthpolicy-toc-womens-health-policy-experiences-womens-health-policy-experiencesreproductive-womens-health-policy-experiences-reproductive-maternal–womens-health-policy-experiences-reproductive-maternal-fert,

Accessed date: 20 October 2017.

Noar, S.M., 2006. A 10-Year Retrospective of Research in Health Mass Media Campaigns: Where Do We Go from Here? J. Health Commun. 11 (1), 21–42.

Petersen, K.B., Hvidman, H.W., Forman, J.L., Pinborg, A., Larsen, E.C., Macklon, K.T., Sylvest, R., Andersen, A.N., 2015. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Hum. Reprod. 30 (10), 2364–2375.

Serour, G.I., 2002. Attitudes and cultural perspectives on infertility and its alleviation in the Middle East area. In: Vayena, E., Rowe, P.J., Griffin, P.D. (Eds.), Current Practices and Controversies in Assisted Reproduction. World Health Organization, Geneva, Switzerland, pp. 41–49.

Sexty, R.E., Hamachek, J., Rösser, S., Strowitzki, T., Ditzen, B., Toth, B., Wischmann, T., 2016. Cross-cultural comparison of fertility specific quality of life in German, Hungarian and Jordanian couples attending a fertility center. Health Qual. Life Outcomes 14 (1), 27.

Sharma, S., Mittal, S., Aggarwal, P., 2009. Management of infertility in low resource countries. BJOG 116 (Suppl. 1), 77–83.

Sullivan, E.A., Zegers-Hochschild, F., Mansour, R., Ishihara, O., de Mouzon, J., Nygren, K.G., Adamson, G.D., 2013. International Committee for Monitoring Assisted Reproductive Technologies (ICMART) world report: assisted reproductive technology 2004. Hum. Reprod. 28 (5), 1375–1390.
An evaluation of comprehensiveness, feasibility and acceptability of a fertility awareness educational tool

Thaddeus, S., Maine, D., 1994. Too far to walk: maternal mortality in context. Soc. Sci. Med. 38 (8), 1091–1110.
The Organisation for Economic Co-operation and Development, 2017. DAC List of ODA Recipients. Retrieved from http://www.oecd.org/dac/stats/daclist.htm.
Tschudin, S., Bunting, L., Abraham, J., Gallop-Evans, E., Flander, A., Boivin, J., 2010. Correlates of fertility issues in an internet survey of cancer survivors. J. Psychosom. Obstet. Gynaecol. 31 (3), 150–157.
United Nations (UN) General Assembly, 2015. Transforming Our World: The 2030 Agenda for Sustainable Development. New York: UN. Retrieved from: http://sustainabledevelopment.un.org/post2015/transformingourworld.
Van der Poel, S.Z., World Health Organization, 2012. Historical walk: the HRP special programme and infertility. Gynecol. Obstet. Investig. 74, 218–227.
World Health Organization, 2005. Decision-making tool for family planning clients and providers: A resource for high-quality counselling. Department of Reproductive Health and Research. WHO Retrieved from http://www.who.int/reproductivehealth/publications/family_planning/9241593229index/en/.
World Health Organization, 2009. Global Health Risk Report, Chapter 2: Global patterns of health risk. Retrieved from http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf.
World Health Organization, 2011. World Report on Disability.
World Health Organization, 2017. Sexual health and its linkages to reproductive health: an operational approach.
World Health Organization, Reproductive Health and Research, 2004. Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets: Global strategy adopted by the 57th World Health Assembly. Retrieved from: http://www.who.int/reproductivehealth/publications/general/RHR_04_8/en/.
Zegers-Hochschild, F., Adamson, G.D., Dyer, S., Racowsky, C., de Mouzon, J., Sokol, R., Rienzi, L., Sunde, A., Schmidt, L., Simpson, J.L., van der Poel, S., 2017. The International Glossary on Infertility and Fertility Care, 2017. Hum. Reprod. 1–16 https://doi.org/10.1093/humrep/dex234.

Received 8 August 2017; refereed 26 April 2018; accepted 25 June 2018.